Methotrexate Drug Interactions
289Total Interactions
70Severe
15Moderate
1Mild
| Drug | Severity | Summary |
|---|---|---|
| Aceclofenac | SEVERE | Aceclofenac is predicted to increase the risk of toxicity when given with Methotrexate (particula... |
| Alcohol | SEVERE | Alcohol -induced liver disease increases the risk of hepatotoxicity in those taking Methotrexate.... |
| Amoxicillin | SEVERE | Amoxicillin is predicted to increase the risk of toxicity when given with Methotrexate. Manufactu... |
| Ampicillin | SEVERE | Ampicillin is predicted to increase the risk of toxicity when given with Methotrexate. Manufactur... |
| Asparaginase | SEVERE | Asparaginase affects the efficacy of Methotrexate. Manufacturer advises separating administration. |
| Aspirin | SEVERE | Aspirin (high-dose) is predicted to increase the risk of toxicity when given with Methotrexate. M... |
| Bacillus Calmette-Guérin vaccine | SEVERE | Bacillus Calmette-Guérin vaccine is predicted to increase the risk of generalised infection (poss... |
| Baricitinib | SEVERE | Baricitinib is predicted to enhance the risk of immunosuppression when given with Methotrexate. M... |
| Bemiparin | SEVERE | Methotrexate might increase the risk of hepatotoxicity when given with Bemiparin (high-dose). Man... |
| Benzathine benzylpenicillin | SEVERE | Benzathine benzylpenicillin is predicted to increase the risk of toxicity when given with Methotr... |
| Benzydamine | SEVERE | Benzydamine is predicted to increase the risk of toxicity when given with Methotrexate (particula... |
| Benzylpenicillin | SEVERE | Benzylpenicillin is predicted to increase the risk of toxicity when given with Methotrexate. Manu... |
| Bromfenac | SEVERE | Bromfenac is predicted to increase the risk of toxicity when given with Methotrexate (particularl... |
| Celecoxib | SEVERE | Celecoxib is predicted to increase the risk of toxicity when given with Methotrexate (particularl... |
| Chikungunya vaccine (live) | SEVERE | Chikungunya vaccine (live) is predicted to increase the risk of generalised infection (possibly l... |
| Cholera vaccine (live) | SEVERE | Cholera vaccine (live) is predicted to increase the risk of generalised infection (possibly life-... |
| Ciprofloxacin | SEVERE | Ciprofloxacin potentially increases the risk of toxicity when given with Methotrexate. Manufactur... |
| Crisantaspase | SEVERE | Crisantaspase affects the efficacy of Methotrexate. Manufacturer advises separating administration. |
| Dalteparin | SEVERE | Methotrexate might increase the risk of hepatotoxicity when given with Dalteparin (high-dose). Ma... |
| Dengue vaccine | SEVERE | Dengue vaccine is predicted to increase the risk of generalised infection (possibly life-threaten... |
| Dexketoprofen | SEVERE | Dexketoprofen is predicted to increase the risk of toxicity when given with Methotrexate (particu... |
| Diclofenac | SEVERE | Diclofenac is predicted to increase the risk of toxicity when given with Methotrexate (particular... |
| Enoxaparin | SEVERE | Methotrexate might increase the risk of hepatotoxicity when given with Enoxaparin (high-dose). Ma... |
| Esomeprazole | SEVERE | Esomeprazole decreases the clearance of Methotrexate (high-dose). Manufacturer advises use with c... |
| Etodolac | SEVERE | Etodolac is predicted to increase the risk of toxicity when given with Methotrexate (particularly... |
| Etoricoxib | SEVERE | Etoricoxib is predicted to increase the risk of toxicity when given with Methotrexate (particular... |
| Flucloxacillin | SEVERE | Flucloxacillin is predicted to increase the risk of toxicity when given with Methotrexate. Manufa... |
| Fluorouracil | SEVERE | Methotrexate potentially increases the risk of severe skin reaction when given with topical Fluor... |
| Flurbiprofen | SEVERE | Flurbiprofen is predicted to increase the risk of toxicity when given with Methotrexate (particul... |
| Ibuprofen | SEVERE | Ibuprofen is predicted to increase the risk of toxicity when given with Methotrexate (particularl... |
| Indometacin | SEVERE | Indometacin is predicted to increase the risk of toxicity when given with Methotrexate (particula... |
| Influenza vaccine (live) | SEVERE | Influenza vaccine (live) is predicted to increase the risk of generalised infection (possibly lif... |
| Ketoprofen | SEVERE | Ketoprofen is predicted to increase the risk of toxicity when given with Methotrexate (particular... |
| Ketorolac | SEVERE | Ketorolac is predicted to increase the risk of toxicity when given with Methotrexate (particularl... |
| Lansoprazole | SEVERE | Lansoprazole decreases the clearance of Methotrexate (high-dose). Manufacturer advises use with c... |
| Leflunomide | SEVERE | Leflunomide is predicted to increase the exposure to Methotrexate. Manufacturer advises avoid. |
| Levetiracetam | SEVERE | Levetiracetam decreases the clearance of Methotrexate. Manufacturer advises monitor Levetiracetam... |
| Measles, mumps and rubella vaccine | SEVERE | Measles, mumps and rubella vaccine is predicted to increase the risk of generalised infection (po... |
| Mefenamic acid | SEVERE | Mefenamic acid is predicted to increase the risk of toxicity when given with Methotrexate (partic... |
| Meloxicam | SEVERE | Meloxicam is predicted to increase the risk of toxicity when given with Methotrexate (particularl... |
| Nabumetone | SEVERE | Nabumetone is predicted to increase the risk of toxicity when given with Methotrexate (particular... |
| Naproxen | SEVERE | Naproxen is predicted to increase the risk of toxicity when given with Methotrexate (particularly... |
| Nepafenac | SEVERE | Nepafenac is predicted to increase the risk of toxicity when given with Methotrexate (particularl... |
| Nitrous oxide | SEVERE | Nitrous oxide potentially increases the risk of Methotrexate toxicity when given with Methotrexat... |
| Omeprazole | SEVERE | Omeprazole decreases the clearance of Methotrexate (high-dose). Manufacturer advises use with cau... |
| Pantoprazole | SEVERE | Pantoprazole decreases the clearance of Methotrexate (high-dose). Manufacturer advises use with c... |
| Parecoxib | SEVERE | Parecoxib is predicted to increase the risk of toxicity when given with Methotrexate (particularl... |
| Pegaspargase | SEVERE | Pegaspargase affects the efficacy of Methotrexate. Manufacturer advises separating administration. |
| Phenazone | SEVERE | Phenazone is predicted to increase the risk of toxicity when given with Methotrexate (particularl... |
| Phenoxymethylpenicillin | SEVERE | Phenoxymethylpenicillin is predicted to increase the risk of toxicity when given with Methotrexat... |
| Piperacillin | SEVERE | Piperacillin is predicted to increase the risk of toxicity when given with Methotrexate. Manufact... |
| Piroxicam | SEVERE | Piroxicam is predicted to increase the risk of toxicity when given with Methotrexate (particularl... |
| Pivmecillinam | SEVERE | Pivmecillinam is predicted to increase the risk of toxicity when given with Methotrexate. Manufac... |
| Pyrimethamine | SEVERE | Pyrimethamine is predicted to increase the risk of adverse effects when given with Methotrexate. ... |
| Rabeprazole | SEVERE | Rabeprazole decreases the clearance of Methotrexate (high-dose). Manufacturer advises use with ca... |
| Rotavirus vaccine | SEVERE | Rotavirus vaccine is predicted to increase the risk of generalised infection (possibly life-threa... |
| Sulfadiazine | SEVERE | Sulfadiazine is predicted to increase the exposure to Methotrexate. Manufacturer advises use with... |
| Sulfamethoxazole | SEVERE | Sulfamethoxazole is predicted to increase the exposure to Methotrexate. Manufacturer advises use ... |
| Sulindac | SEVERE | Sulindac is predicted to increase the risk of toxicity when given with Methotrexate (particularly... |
| Tegafur | SEVERE | Methotrexate is predicted to increase the risk of toxicity when given with Tegafur. Manufacturer ... |
| Temocillin | SEVERE | Temocillin is predicted to increase the risk of toxicity when given with Methotrexate. Manufactur... |
| Tenoxicam | SEVERE | Tenoxicam is predicted to increase the risk of toxicity when given with Methotrexate (particularl... |
| Tiaprofenic acid | SEVERE | Tiaprofenic acid is predicted to increase the risk of toxicity when given with Methotrexate (part... |
| Tinzaparin | SEVERE | Methotrexate might increase the risk of hepatotoxicity when given with Tinzaparin (high-dose). Ma... |
| Tolfenamic acid | SEVERE | Tolfenamic acid is predicted to increase the risk of toxicity when given with Methotrexate (parti... |
| Trimethoprim | SEVERE | Trimethoprim increases the risk of haematological side-effects (sometimes fatal) when given with ... |
| Typhoid vaccine (live) | SEVERE | Typhoid vaccine (live) is predicted to increase the risk of generalised infection (possibly life-... |
| Valproate | SEVERE | Methotrexate might decrease the concentration of Valproate. Manufacturer advises monitor. |
| Varicella-zoster vaccine | SEVERE | Varicella-zoster vaccine is predicted to increase the risk of generalised infection (possibly lif... |
| Yellow fever vaccine | SEVERE | Yellow fever vaccine is predicted to increase the risk of generalised infection (possibly life-th... |
| Acetazolamide | MODERATE | Acetazolamide increases the urinary excretion of Methotrexate. Manufacturer makes no recommendation. |
| Acitretin | MODERATE | Acitretin is predicted to increase the concentration of Methotrexate. Manufacturer advises avoid. |
| Aminophylline | MODERATE | Methotrexate is predicted to decrease the clearance of Aminophylline. Manufacturer makes no recom... |
| Darolutamide | MODERATE | Darolutamide is predicted to increase the concentration of Methotrexate. Manufacturer advises mon... |
| Eltrombopag | MODERATE | Eltrombopag is predicted to increase the concentration of Methotrexate. Manufacturer advises caut... |
| Ivosidenib | MODERATE | Ivosidenib is predicted to increase the exposure to Methotrexate. Manufacturer advises use with c... |
| Nitisinone | MODERATE | Nitisinone is predicted to increase the exposure to Methotrexate. Manufacturer makes no recommend... |
| Pirtobrutinib | MODERATE | Pirtobrutinib is predicted to increase the exposure to Methotrexate. Manufacturer advises caution. |
| Potassium aminobenzoate | MODERATE | Potassium aminobenzoate increases the concentration of Methotrexate. Manufacturer makes no recomm... |
| Regorafenib | MODERATE | Regorafenib is predicted to increase the exposure to Methotrexate. Manufacturer advises monitor a... |
| Sapropterin | MODERATE | Methotrexate is predicted to decrease the efficacy of Sapropterin. Manufacturer advises caution. |
| Tedizolid | MODERATE | Tedizolid is predicted to increase the exposure to Methotrexate. Manufacturer advises avoid. |
| Teriflunomide | MODERATE | Teriflunomide is predicted to increase the exposure to Methotrexate. Manufacturer advises caution. |
| Theophylline | MODERATE | Methotrexate decreases the clearance of Theophylline. Manufacturer makes no recommendation. |
| Vadadustat | MODERATE | Vadadustat is predicted to increase the exposure to Methotrexate. Manufacturer advises monitor an... |
| Apalutamide | MILD | Apalutamide is predicted to decrease the exposure to Methotrexate. Manufacturer advises monitor. |
| Aciclovir | LOW | Both Methotrexate and Aciclovir can increase the risk of nephrotoxicity. |
| Adalimumab | LOW | Both Methotrexate and Adalimumab can increase the risk of myelosuppression. |
| Aldesleukin | LOW | Both Methotrexate and Aldesleukin can increase the risk of myelosuppression. |
| Alectinib | LOW | Both Methotrexate and Alectinib can increase the risk of hepatotoxicity. |
| Alemtuzumab | LOW | Both Methotrexate and Alemtuzumab can increase the risk of myelosuppression. |
| Amikacin | LOW | Both Methotrexate and Amikacin can increase the risk of nephrotoxicity. |
| Amiodarone | LOW | Both Methotrexate and Amiodarone can increase the risk of hepatotoxicity. |
| Amphotericin B | LOW | Both Methotrexate and Amphotericin B can increase the risk of nephrotoxicity. |
| Amsacrine | LOW | Both Methotrexate and Amsacrine can increase the risk of myelosuppression. |
| Anidulafungin | LOW | Both Methotrexate and Anidulafungin can increase the risk of hepatotoxicity. |
| Arsenic trioxide | LOW | Both Methotrexate and Arsenic trioxide can increase the risk of myelosuppression. |
| Atorvastatin | LOW | Both Methotrexate and Atorvastatin can increase the risk of hepatotoxicity. |
| Axitinib | LOW | Both Methotrexate and Axitinib can increase the risk of myelosuppression. |
| Azacitidine | LOW | Both Methotrexate and Azacitidine can increase the risk of myelosuppression. |
| Azathioprine | LOW | Both Methotrexate and Azathioprine can increase the risk of myelosuppression. |
| Belatacept | LOW | Both Methotrexate and Belatacept can increase the risk of myelosuppression. |
| Bendamustine | LOW | Both Methotrexate and Bendamustine can increase the risk of myelosuppression. |
| Bevacizumab | LOW | Both Methotrexate and Bevacizumab can increase the risk of myelosuppression. |
| Bexarotene | LOW | Both Methotrexate and Bexarotene can increase the risk of hepatotoxicity. |
| Bleomycin | LOW | Both Methotrexate and Bleomycin can increase the risk of myelosuppression. |
| Blinatumomab | LOW | Both Methotrexate and Blinatumomab can increase the risk of myelosuppression. |
| Bortezomib | LOW | Both Methotrexate and Bortezomib can increase the risk of myelosuppression. |
| Bosutinib | LOW | Both Methotrexate and Bosutinib can increase the risk of myelosuppression. |
| Brentuximab vedotin | LOW | Both Methotrexate and Brentuximab vedotin can increase the risk of myelosuppression. |
| Busulfan | LOW | Both Methotrexate and Busulfan can increase the risk of myelosuppression. |
| Cabazitaxel | LOW | Both Methotrexate and Cabazitaxel can increase the risk of myelosuppression. |
| Cabozantinib | LOW | Both Methotrexate and Cabozantinib can increase the risk of myelosuppression. |
| Canakinumab | LOW | Both Methotrexate and Canakinumab can increase the risk of myelosuppression. |
| Capecitabine | LOW | Both Methotrexate and Capecitabine can increase the risk of hepatotoxicity. |
| Captopril | LOW | Both Methotrexate and Captopril can increase the risk of nephrotoxicity. |
| Carboplatin | LOW | Both Methotrexate and Carboplatin can increase the risk of myelosuppression. |
| Carfilzomib | LOW | Both Methotrexate and Carfilzomib can increase the risk of myelosuppression. |
| Carmustine | LOW | Both Methotrexate and Carmustine can increase the risk of hepatotoxicity. |
| Caspofungin | LOW | Both Methotrexate and Caspofungin can increase the risk of hepatotoxicity. |
| Cefaclor | LOW | Both Methotrexate and Cefaclor can increase the risk of nephrotoxicity. |
| Cefadroxil | LOW | Both Methotrexate and Cefadroxil can increase the risk of nephrotoxicity. |
| Cefalexin | LOW | Both Methotrexate and Cefalexin can increase the risk of nephrotoxicity. |
| Cefazolin | LOW | Both Methotrexate and Cefazolin can increase the risk of nephrotoxicity. |
| Cefepime | LOW | Both Methotrexate and Cefepime can increase the risk of nephrotoxicity. |
| Cefixime | LOW | Both Methotrexate and Cefixime can increase the risk of nephrotoxicity. |
| Cefotaxime | LOW | Both Methotrexate and Cefotaxime can increase the risk of nephrotoxicity. |
| Cefoxitin | LOW | Both Methotrexate and Cefoxitin can increase the risk of nephrotoxicity. |
| Cefradine | LOW | Both Methotrexate and Cefradine can increase the risk of nephrotoxicity. |
| Ceftaroline | LOW | Both Methotrexate and Ceftaroline can increase the risk of nephrotoxicity. |
| Ceftazidime | LOW | Both Methotrexate and Ceftazidime can increase the risk of nephrotoxicity. |
| Ceftobiprole | LOW | Both Methotrexate and Ceftobiprole can increase the risk of nephrotoxicity. |
| Ceftolozane | LOW | Both Methotrexate and Ceftolozane can increase the risk of nephrotoxicity. |
| Ceftriaxone | LOW | Both Methotrexate and Ceftriaxone can increase the risk of nephrotoxicity. |
| Cefuroxime | LOW | Both Methotrexate and Cefuroxime can increase the risk of nephrotoxicity. |
| Ceritinib | LOW | Both Methotrexate and Ceritinib can increase the risk of myelosuppression. |
| Certolizumab pegol | LOW | Both Methotrexate and Certolizumab pegol can increase the risk of myelosuppression. |
| Chlorambucil | LOW | Both Methotrexate and Chlorambucil can increase the risk of myelosuppression. |
| Ciclosporin | LOW | Both Methotrexate and Ciclosporin can increase the risk of nephrotoxicity. |
| Cidofovir | LOW | Both Methotrexate and Cidofovir can increase the risk of nephrotoxicity. |
| Cisplatin | LOW | Both Methotrexate and Cisplatin can increase the risk of myelosuppression. |
| Cladribine | LOW | Both Methotrexate and Cladribine can increase the risk of myelosuppression. |
| Clofarabine | LOW | Both Methotrexate and Clofarabine can increase the risk of hepatotoxicity. |
| Colistimethate | LOW | Both Methotrexate and Colistimethate can increase the risk of nephrotoxicity. |
| Cyclophosphamide | LOW | Both Methotrexate and Cyclophosphamide can increase the risk of myelosuppression. |
| Cytarabine | LOW | Both Methotrexate and Cytarabine can increase the risk of hepatotoxicity. |
| Dacarbazine | LOW | Both Methotrexate and Dacarbazine can increase the risk of myelosuppression. |
| Dactinomycin | LOW | Both Methotrexate and Dactinomycin can increase the risk of hepatotoxicity. |
| Daratumumab | LOW | Both Methotrexate and Daratumumab can increase the risk of myelosuppression. |
| Dasatinib | LOW | Both Methotrexate and Dasatinib can increase the risk of myelosuppression. |
| Daunorubicin | LOW | Both Methotrexate and Daunorubicin can increase the risk of myelosuppression. |
| Decitabine | LOW | Both Methotrexate and Decitabine can increase the risk of hepatotoxicity. |
| Deferasirox | LOW | Both Methotrexate and Deferasirox can increase the risk of nephrotoxicity. |
| Demeclocycline | LOW | Both Methotrexate and Demeclocycline can increase the risk of hepatotoxicity. |
| Dexrazoxane | LOW | Both Methotrexate and Dexrazoxane can increase the risk of myelosuppression. |
| Dinutuximab | LOW | Both Methotrexate and Dinutuximab can increase the risk of myelosuppression. |
| Docetaxel | LOW | Both Methotrexate and Docetaxel can increase the risk of myelosuppression. |
| Doxorubicin | LOW | Both Methotrexate and Doxorubicin can increase the risk of myelosuppression. |
| Doxycycline | LOW | Both Methotrexate and Doxycycline can increase the risk of hepatotoxicity. |
| Enalapril | LOW | Both Methotrexate and Enalapril can increase the risk of nephrotoxicity. |
| Epirubicin | LOW | Both Methotrexate and Epirubicin can increase the risk of myelosuppression. |
| Eravacycline | LOW | Both Methotrexate and Eravacycline can increase the risk of hepatotoxicity. |
| Eribulin | LOW | Both Methotrexate and Eribulin can increase the risk of myelosuppression. |
| Estramustine | LOW | Both Methotrexate and Estramustine can increase the risk of myelosuppression. |
| Etoposide | LOW | Both Methotrexate and Etoposide can increase the risk of myelosuppression. |
| Fluconazole | LOW | Both Methotrexate and Fluconazole can increase the risk of hepatotoxicity. |
| Fludarabine | LOW | Both Methotrexate and Fludarabine can increase the risk of hepatotoxicity. |
| Flutamide | LOW | Both Methotrexate and Flutamide can increase the risk of hepatotoxicity. |
| Fluvastatin | LOW | Both Methotrexate and Fluvastatin can increase the risk of hepatotoxicity. |
| Foscarnet | LOW | Both Methotrexate and Foscarnet can increase the risk of nephrotoxicity. |
| Fosinopril | LOW | Both Methotrexate and Fosinopril can increase the risk of nephrotoxicity. |
| Ganciclovir | LOW | Both Methotrexate and Ganciclovir can increase the risk of myelosuppression. |
| Gemcitabine | LOW | Both Methotrexate and Gemcitabine can increase the risk of hepatotoxicity. |
| Gemtuzumab ozogamicin | LOW | Both Methotrexate and Gemtuzumab ozogamicin can increase the risk of myelosuppression. |
| Gentamicin | LOW | Both Methotrexate and Gentamicin can increase the risk of nephrotoxicity. |
| Golimumab | LOW | Both Methotrexate and Golimumab can increase the risk of myelosuppression. |
| Heparin | LOW | Both Methotrexate and Heparin can increase the risk of hepatotoxicity. |
| Hydroxycarbamide | LOW | Both Methotrexate and Hydroxycarbamide can increase the risk of myelosuppression. |
| Ibrutinib | LOW | Both Methotrexate and Ibrutinib can increase the risk of myelosuppression. |
| Idarubicin | LOW | Both Methotrexate and Idarubicin can increase the risk of myelosuppression. |
| Ifosfamide | LOW | Both Methotrexate and Ifosfamide can increase the risk of myelosuppression. |
| Imatinib | LOW | Both Methotrexate and Imatinib can increase the risk of myelosuppression. |
| Imidapril | LOW | Both Methotrexate and Imidapril can increase the risk of nephrotoxicity. |
| Infliximab | LOW | Both Methotrexate and Infliximab can increase the risk of myelosuppression. |
| Inotersen | LOW | Both Methotrexate and Inotersen can increase the risk of nephrotoxicity. |
| Inotuzumab ozogamicin | LOW | Both Methotrexate and Inotuzumab ozogamicin can increase the risk of myelosuppression. |
| Ipilimumab | LOW | Both Methotrexate and Ipilimumab can increase the risk of myelosuppression. |
| Irinotecan | LOW | Both Methotrexate and Irinotecan can increase the risk of myelosuppression. |
| Isoniazid | LOW | Both Methotrexate and Isoniazid can increase the risk of hepatotoxicity. |
| Isotretinoin | LOW | Both Methotrexate and Isotretinoin can increase the risk of hepatotoxicity. |
| Itraconazole | LOW | Both Methotrexate and Itraconazole can increase the risk of hepatotoxicity. |
| Lenalidomide | LOW | Both Methotrexate and Lenalidomide can increase the risk of hepatotoxicity. |
| Lisinopril | LOW | Both Methotrexate and Lisinopril can increase the risk of nephrotoxicity. |
| Lithium | LOW | Both Methotrexate and Lithium can increase the risk of nephrotoxicity. |
| Lomitapide | LOW | Both Methotrexate and Lomitapide can increase the risk of hepatotoxicity. |
| Lomustine | LOW | Both Methotrexate and Lomustine can increase the risk of myelosuppression. |
| Lymecycline | LOW | Both Methotrexate and Lymecycline can increase the risk of hepatotoxicity. |
| Melphalan | LOW | Both Methotrexate and Melphalan can increase the risk of myelosuppression. |
| Mercaptopurine | LOW | Both Methotrexate and Mercaptopurine can increase the risk of hepatotoxicity. |
| Mesalazine | LOW | Both Methotrexate and Mesalazine can increase the risk of nephrotoxicity. |
| Micafungin | LOW | Both Methotrexate and Micafungin can increase the risk of hepatotoxicity. |
| Mifamurtide | LOW | Both Methotrexate and Mifamurtide can increase the risk of myelosuppression. |
| Minocycline | LOW | Both Methotrexate and Minocycline can increase the risk of hepatotoxicity. |
| Mitomycin | LOW | Both Methotrexate and Mitomycin can increase the risk of myelosuppression. |
| Mitotane | LOW | Both Methotrexate and Mitotane can increase the risk of myelosuppression. |
| Mitoxantrone | LOW | Both Methotrexate and Mitoxantrone can increase the risk of myelosuppression. |
| Mogamulizumab | LOW | Both Methotrexate and Mogamulizumab can increase the risk of myelosuppression. |
| Nelarabine | LOW | Both Methotrexate and Nelarabine can increase the risk of hepatotoxicity. |
| Neomycin | LOW | Both Methotrexate and Neomycin can increase the risk of nephrotoxicity. |
| Neratinib | LOW | Both Methotrexate and Neratinib can increase the risk of hepatotoxicity. |
| Netilmicin | LOW | Both Methotrexate and Netilmicin can increase the risk of nephrotoxicity. |
| Nevirapine | LOW | Both Methotrexate and Nevirapine can increase the risk of hepatotoxicity. |
| Nicotinic acid | LOW | Both Methotrexate and Nicotinic acid can increase the risk of hepatotoxicity. |
| Nilotinib | LOW | Both Methotrexate and Nilotinib can increase the risk of myelosuppression. |
| Niraparib | LOW | Both Methotrexate and Niraparib can increase the risk of myelosuppression. |
| Nivolumab | LOW | Both Methotrexate and Nivolumab can increase the risk of myelosuppression. |
| Obinutuzumab | LOW | Both Methotrexate and Obinutuzumab can increase the risk of myelosuppression. |
| Olaparib | LOW | Both Methotrexate and Olaparib can increase the risk of myelosuppression. |
| Oxaliplatin | LOW | Both Methotrexate and Oxaliplatin can increase the risk of myelosuppression. |
| Oxandrolone | LOW | Both Methotrexate and Oxandrolone can increase the risk of hepatotoxicity. |
| Oxymetholone | LOW | Both Methotrexate and Oxymetholone can increase the risk of hepatotoxicity. |
| Oxytetracycline | LOW | Both Methotrexate and Oxytetracycline can increase the risk of hepatotoxicity. |
| Paclitaxel | LOW | Both Methotrexate and Paclitaxel can increase the risk of myelosuppression. |
| Palbociclib | LOW | Both Methotrexate and Palbociclib can increase the risk of myelosuppression. |
| Pamidronate | LOW | Both Methotrexate and Pamidronate can increase the risk of nephrotoxicity. |
| Panobinostat | LOW | Both Methotrexate and Panobinostat can increase the risk of myelosuppression. |
| Paracetamol | LOW | Both Methotrexate and Paracetamol can increase the risk of hepatotoxicity. |
| Peginterferon alfa | LOW | Both Methotrexate and Peginterferon alfa can increase the risk of myelosuppression. |
| Pembrolizumab | LOW | Both Methotrexate and Pembrolizumab can increase the risk of myelosuppression. |
| Pemetrexed | LOW | Both Methotrexate and Pemetrexed can increase the risk of hepatotoxicity. |
| Pentamidine | LOW | Both Methotrexate and Pentamidine can increase the risk of nephrotoxicity. |
| Pentostatin | LOW | Both Methotrexate and Pentostatin can increase the risk of myelosuppression. |
| Perindopril | LOW | Both Methotrexate and Perindopril can increase the risk of nephrotoxicity. |
| Pixantrone | LOW | Both Methotrexate and Pixantrone can increase the risk of myelosuppression. |
| Pomalidomide | LOW | Both Methotrexate and Pomalidomide can increase the risk of hepatotoxicity. |
| Pravastatin | LOW | Both Methotrexate and Pravastatin can increase the risk of hepatotoxicity. |
| Procarbazine | LOW | Both Methotrexate and Procarbazine can increase the risk of myelosuppression. |
| Pyrazinamide | LOW | Both Methotrexate and Pyrazinamide can increase the risk of hepatotoxicity. |
| Quinapril | LOW | Both Methotrexate and Quinapril can increase the risk of nephrotoxicity. |
| Raltitrexed | LOW | Both Methotrexate and Raltitrexed can increase the risk of myelosuppression. |
| Ramipril | LOW | Both Methotrexate and Ramipril can increase the risk of nephrotoxicity. |
| Ramucirumab | LOW | Both Methotrexate and Ramucirumab can increase the risk of myelosuppression. |
| Ribociclib | LOW | Both Methotrexate and Ribociclib can increase the risk of myelosuppression. |
| Rifampicin | LOW | Both Methotrexate and Rifampicin can increase the risk of nephrotoxicity. |
| Ritonavir | LOW | Both Methotrexate and Ritonavir can increase the risk of hepatotoxicity. |
| Rituximab | LOW | Both Methotrexate and Rituximab can increase the risk of myelosuppression. |
| Ropeginterferon alfa | LOW | Both Methotrexate and Ropeginterferon alfa can increase the risk of myelosuppression. |
| Rosuvastatin | LOW | Both Methotrexate and Rosuvastatin can increase the risk of hepatotoxicity. |
| Rucaparib | LOW | Both Methotrexate and Rucaparib can increase the risk of myelosuppression. |
| Ruxolitinib | LOW | Both Methotrexate and Ruxolitinib can increase the risk of myelosuppression. |
| Simvastatin | LOW | Both Methotrexate and Simvastatin can increase the risk of hepatotoxicity. |
| Sorafenib | LOW | Both Methotrexate and Sorafenib can increase the risk of myelosuppression. |
| Sotorasib | LOW | Both Methotrexate and Sotorasib can increase the risk of hepatotoxicity. |
| Streptomycin | LOW | Both Methotrexate and Streptomycin can increase the risk of nephrotoxicity. |
| Streptozocin | LOW | Both Methotrexate and Streptozocin can increase the risk of hepatotoxicity. |
| Sulfasalazine | LOW | Both Methotrexate and Sulfasalazine can increase the risk of myelosuppression. |
| Sunitinib | LOW | Both Methotrexate and Sunitinib can increase the risk of myelosuppression. |
| Tacrolimus | LOW | Both Methotrexate and Tacrolimus can increase the risk of nephrotoxicity. |
| Talazoparib | LOW | Both Methotrexate and Talazoparib can increase the risk of myelosuppression. |
| Temozolomide | LOW | Both Methotrexate and Temozolomide can increase the risk of myelosuppression. |
| Temsirolimus | LOW | Both Methotrexate and Temsirolimus can increase the risk of myelosuppression. |
| Tenofovir disoproxil | LOW | Both Methotrexate and Tenofovir disoproxil can increase the risk of nephrotoxicity. |
| Testosterone | LOW | Both Methotrexate and Testosterone can increase the risk of hepatotoxicity. |
| Tetracycline | LOW | Both Methotrexate and Tetracycline can increase the risk of hepatotoxicity. |
| Thalidomide | LOW | Both Methotrexate and Thalidomide can increase the risk of hepatotoxicity. |
| Thiotepa | LOW | Both Methotrexate and Thiotepa can increase the risk of myelosuppression. |
| Tigecycline | LOW | Both Methotrexate and Tigecycline can increase the risk of hepatotoxicity. |
| Tioguanine | LOW | Both Methotrexate and Tioguanine can increase the risk of hepatotoxicity. |
| Tobramycin | LOW | Both Methotrexate and Tobramycin can increase the risk of nephrotoxicity. |
| Topotecan | LOW | Both Methotrexate and Topotecan can increase the risk of myelosuppression. |
| Trabectedin | LOW | Both Methotrexate and Trabectedin can increase the risk of hepatotoxicity. |
| Trandolapril | LOW | Both Methotrexate and Trandolapril can increase the risk of nephrotoxicity. |
| Trastuzumab | LOW | Both Methotrexate and Trastuzumab can increase the risk of myelosuppression. |
| Trastuzumab deruxtecan | LOW | Both Methotrexate and Trastuzumab deruxtecan can increase the risk of myelosuppression. |
| Trastuzumab emtansine | LOW | Both Methotrexate and Trastuzumab emtansine can increase the risk of myelosuppression. |
| Treosulfan | LOW | Both Methotrexate and Treosulfan can increase the risk of myelosuppression. |
| Valaciclovir | LOW | Both Methotrexate and Valaciclovir can increase the risk of nephrotoxicity. |
| Valganciclovir | LOW | Both Methotrexate and Valganciclovir can increase the risk of myelosuppression. |
| Vancomycin | LOW | Both Methotrexate and Vancomycin can increase the risk of nephrotoxicity. |
| Vinblastine | LOW | Both Methotrexate and Vinblastine can increase the risk of myelosuppression. |
| Vincristine | LOW | Both Methotrexate and Vincristine can increase the risk of myelosuppression. |
| Vindesine | LOW | Both Methotrexate and Vindesine can increase the risk of myelosuppression. |
| Vinorelbine | LOW | Both Methotrexate and Vinorelbine can increase the risk of myelosuppression. |
| Vitamin A | LOW | Both Methotrexate and Vitamin A can increase the risk of hepatotoxicity. |
| Voclosporin | LOW | Both Methotrexate and Voclosporin can increase the risk of nephrotoxicity. |
| Vorasidenib | LOW | Both Methotrexate and Vorasidenib can increase the risk of hepatotoxicity. |
| Voriconazole | LOW | Both Methotrexate and Voriconazole can increase the risk of hepatotoxicity. |
| Zidovudine | LOW | Both Methotrexate and Zidovudine can increase the risk of hepatotoxicity. |
| Zoledronate | LOW | Both Methotrexate and Zoledronate can increase the risk of nephrotoxicity. |
Check Methotrexate against your patient's full medication list
InteractRx checks all drug combinations at once — built for GP surgery pharmacists.
Use the Free Checker